<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>7(3)</volume><submitter>Trotman J</submitter><journal>HemaSphere</journal><pagination>e836</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9946407</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive After Treatment for Relapsed Follicular Lymphoma: A Phase 2 Australasian Leukaemia &amp; Lymphoma Group NHL26 Study.</pubmed_title><pmcid>PMC9946407</pmcid><pubmed_authors>Carradice DP</pubmed_authors><pubmed_authors>Nkhoma G</pubmed_authors><pubmed_authors>Lenton DS</pubmed_authors><pubmed_authors>Badoux X</pubmed_authors><pubmed_authors>Gandhi MK</pubmed_authors><pubmed_authors>Trotman J</pubmed_authors><pubmed_authors>Butcher B</pubmed_authors><pubmed_authors>Nikpour A</pubmed_authors><pubmed_authors>Presgrave P</pubmed_authors><pubmed_authors>Johnston AM</pubmed_authors><pubmed_authors>Carlson J</pubmed_authors><pubmed_authors>Fulham M</pubmed_authors><pubmed_authors>Cochrane T</pubmed_authors></additional><is_claimable>false</is_claimable><name>Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive After Treatment for Relapsed Follicular Lymphoma: A Phase 2 Australasian Leukaemia &amp; Lymphoma Group NHL26 Study.</name><description/><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Mar</publication><modification>2025-04-22T02:26:14.333Z</modification><creation>2025-04-05T20:19:24.794Z</creation></dates><accession>S-EPMC9946407</accession><cross_references><pubmed>36844180</pubmed><doi>10.1097/HS9.0000000000000836</doi></cross_references></HashMap>